PacBio Files DEF 14A for Annual Meeting

Ticker: PACB · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1299130

Sentiment: neutral

Topics: DEF 14A, Executive Compensation, Annual Meeting, PacBio, Corporate Governance

TL;DR

<b>Pacific Biosciences of California, Inc. filed its DEF 14A, detailing executive compensation and annual meeting information for the fiscal year ending December 31, 2023.</b>

AI Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Pacific Biosciences of California, Inc. filed a DEF 14A form on April 29, 2024. The filing pertains to the company's annual meeting of stockholders. The report covers the fiscal year ending December 31, 2023. Key executive compensation data and equity awards are detailed within the filing. The company's principal executive offices are located at 1305 O'Brien Drive, Menlo Park, CA 94025.

Why It Matters

For investors and stakeholders tracking PACIFIC BIOSCIENCES OF CALIFORNIA, INC., this filing contains several important signals. This DEF 14A filing provides crucial details on executive compensation, including equity awards, which are important for shareholders to understand how management is incentivized. Shareholders can use this filing to make informed decisions regarding voting matters at the upcoming annual meeting, particularly concerning director elections and executive pay.

Risk Assessment

Risk Level: low — PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material financial or operational information, but rather focuses on corporate governance and executive compensation.

Analyst Insight

Shareholders should review the executive compensation tables and proposals for the annual meeting to understand management incentives and vote accordingly.

Key Numbers

Key Players & Entities

FAQ

When did PACIFIC BIOSCIENCES OF CALIFORNIA, INC. file this DEF 14A?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB).

Where can I read the original DEF 14A filing from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by PACIFIC BIOSCIENCES OF CALIFORNIA, INC..

What are the key takeaways from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s DEF 14A?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed this DEF 14A on April 29, 2024. Key takeaways: Pacific Biosciences of California, Inc. filed a DEF 14A form on April 29, 2024.. The filing pertains to the company's annual meeting of stockholders.. The report covers the fiscal year ending December 31, 2023..

Is PACIFIC BIOSCIENCES OF CALIFORNIA, INC. a risky investment based on this filing?

Based on this DEF 14A, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material financial or operational information, but rather focuses on corporate governance and executive compensation.

What should investors do after reading PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s DEF 14A?

Shareholders should review the executive compensation tables and proposals for the annual meeting to understand management incentives and vote accordingly. The overall sentiment from this filing is neutral.

How does PACIFIC BIOSCIENCES OF CALIFORNIA, INC. compare to its industry peers?

Pacific Biosciences of California, Inc. operates in the biotechnology sector, specifically focusing on DNA sequencing technology.

Are there regulatory concerns for PACIFIC BIOSCIENCES OF CALIFORNIA, INC.?

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating companies to provide detailed information to shareholders regarding annual meetings and related matters.

Industry Context

Pacific Biosciences of California, Inc. operates in the biotechnology sector, specifically focusing on DNA sequencing technology.

Regulatory Implications

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating companies to provide detailed information to shareholders regarding annual meetings and related matters.

What Investors Should Do

  1. Review the proxy statement for details on director nominees and their qualifications.
  2. Analyze the executive compensation section to understand pay structures and equity awards.
  3. Examine any shareholder proposals and management's recommendations for voting.

Year-Over-Year Comparison

This filing is a DEF 14A, which is a proxy statement typically filed annually to provide information about the company's annual meeting of stockholders and related matters, including executive compensation.

Filing Stats: 4,874 words · 19 min read · ~16 pages · Grade level 13.3 · Accepted 2024-04-29 08:16:12

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 46 EXECUTIVE OFFICERS 48

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 49

Executive Compensation Tables

Executive Compensation Tables 62 OTHER INFORMATION 77 ANNEX A - AMENDED 2020 EQUITY INCENTIVE PLAN A- 1 ANNEX B - AMENDMENT OF CERTIFICATE OF INCORPORATION TO DECLASSIFY THE BOARD OF DIRECTORS B- 1 ANNEX C - AMENDMENT OF CERTIFICATE OF INCORPORATION TO LIMIT THE LIABILITY OF OFFICERS C-1 i TABLE OF CONTENTS PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1305 O'Brien Drive, Menlo Park, California 94025 PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS To Be Held on June 18, 2024 GENERAL INFORMATION We are furnishing you with these proxy materials in connection with the solicitation by the Board of Directors of Pacific Biosciences of California, Inc. (the "Board of Directors") of proxies to be used at our 2024 Annual Meeting of Stockholders including any adjournments and postponements thereof (the "Annual Meeting"). The Annual Meeting will be at held virtually on June 18, 2024 at 9:00 a.m. Pacific Time on the internet at www.virtualshareholdermeeting.com/PACB2024. You will be able to attend and participate in the Annual Meeting online, vote your shares electronically and submit your questions prior to and during the meeting. To access the virtual meeting, please have your notice or proxy card in hand when you visit the website. This Proxy Statement contains important information regarding our Annual Meeting, the proposals on which you are being asked to vote, information you may find useful in determining how to vote, and information about voting procedures. As used herein, "we," "us," "our," "Pacific Biosciences," "PacBio" or the "Company" refer to Pacific Biosciences of California, Inc., a Delaware corporation. The information provided in the "question and answer" format below is for your convenience only and is merely a summary of the information contained in this Proxy Statement. You should read this entire Proxy Statement carefully. Information contained on, or that can be accessed through, our website is not intended to be incorporate

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing